Conference Coverage
Latest News
Jul 09, 2026 | News
Phase 1b Trial of FB102 Demonstrates Significant Facial Repigmentation and Sustained Vitiligo Response
The 15 Minutes That Can Transform Your Dermatology Practice
Jul 09, 2026
First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo
Jul 09, 2026
Higher Cumulative Isotretinoin Dose May Reduce Acne Relapse
Jul 08, 2026
ICYMI: SkinStylus Gains FDA Clearance for Periorbital Wrinkles Across All Fitzpatrick Skin Types
Jul 08, 2026
Videos
Advertisement
Shorts
0:47
Why Patient Stratification Matters in Clinical Trials
4 hours ago
by
Bradley Burnam
0:56
The Importance of Early PsA Treatment for Joint Health
a day ago
by
Philip J. Mease, MD
0:31
Why Your Acne Treatments May Not Be Working
2 days ago
by
Kord Honda, MD
0:24
Why patients are moving away from injectable psoriasis treatments
3 days ago
by
Linda Stein Gold, MD
1:10
A Win for Patients and Providers: Roflumilast’s Expanded PsO Indication
8 days ago
by
Christopher G. Bunick, MD, PhD
1:00
Roflumilast Cream Approved for Children as Young as 2 With Plaque Psoriasis
9 days ago
by
Jennifer Soung, MD
0:28
Rethinking First-Line Treatment for Atopic Dermatitis
13 days ago
by
David Cotter, MD, PhD
2:18
What AbbVie’s Acquisition of Apogee Means for AD Treatment
13 days ago
by
Christopher G. Bunick, MD, PhD
0:42
When Patients Fear Their AD Medication
14 days ago
by
Mona Shahriari, MD, FAAD
0:35
The Myths Surrounding Food Allergies and Atopic Dermatitis
15 days ago
by
Jennifer Soung, MD
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.
New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.
Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.
Innovations in packaging, formulation design, and alternative preservation strategies may reduce preservative concentrations, but they are unlikely to eliminate the need for preservatives entirely.
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Continuing Medical Education
All News
Advertisement
Advertisement
The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.
This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.
A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.
A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.
Teva will advance TEV-'408 into phase 2b after encouraging phase 1b vitiligo data showed repigmentation, favorable safety, and quarterly dosing potential.
New case-control data link smoking to higher nail psoriasis severity, urging screening and cessation to ease nail symptoms and boost quality of life.
Turn Therapeutics finalized its stage 2 trial design after interim data showed clinically meaningful GX-03 efficacy in patients with baseline EASI scores as low as 1.1.
At a recent Dermatology Times Evolving Paradigms event, Nikhil Khushalani, MD, led dermatologists, Mohs surgeons, and oncologists in comparing systemic immunotherapy selection, referral practices, and adverse event management in advanced cutaneous squamous cell carcinoma.
Can-Fite completed interim enrollment for its pivotal phase 3 trial of first-in-class oral A3AR agonist piclidenoson, a potential new mechanism for plaque psoriasis.
Explore top dermatology conferences and meetings in July 2026 and let us know which ones you'll be attending!
Advertisement
One-year phase 3 VELA data showed durable clinical responses, quality-of-life improvements, and no new safety signals for investigational sonelokimab in hidradenitis suppurativa.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
AbbVie's upadacitinib received a positive CHMP opinion for severe alopecia areata as FDA review continues in the US.
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
The approval expands the existing indication for adults and children down to age 6, includes intertriginous areas, and removes restrictions on duration of use.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With Atopic Dermatitis Down to 3 Months
2
Teva Advances TEV-'408 Into Phase 2b for Vitiligo
3
Higher Cumulative Isotretinoin Dose May Reduce Acne Relapse
4
First-in-Class Oral Piclidenoson Reaches Pivotal Phase 3 Enrollment Milestone in Plaque Psoriasis
5